Analyst Price Targets — AUPH
Latest News for AUPH
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) shares are trading lower Thursday afternoon after the lupus-focused drugmaker posted fourth quarter earnings and raised expectations for continued growth in 2026.
Aurinia Pharmaceuticals Inc. (AUPH) Q4 2025 Earnings Call Transcript
Aurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.21 per share. This compares to earnings of $0.09 per share a year ago.
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and twelve months ended December 31, 2025 and provided an update on recent business progress. Financial Results Total Revenue: For the three and twelve months ended December 31, 2025, total revenue was $77.1 million and $283.1 million, up 29% and 20%, respectively, compared…
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that it will report financial results for the three and twelve months ended December 31, 2025, and provide an update on recent business progress on February 26, 2026. Aurinia's management team will host a webcast and conference call on February 26, 2026, at 8:30 a.m. ET. The link to the webcast is…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for AUPH.
U.S. House Trading
No House trades found for AUPH.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.